Mesothelin Immunotherapy for Cancer: Ready for Prime Time?

被引：242
作者：
Hassan, Raffit [1 ]
Thomas, Anish [1 ]
Alewine, Christine [1 ]
Le, Dung T. [2 ]
Jaffee, Elizabeth M. [2 ]
Pastan, Ira [1 ]
机构：
[1] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] Johns Hopkins Univ, Sidney Kimmel Canc Ctr, Baltimore, MD USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 34期
基金：
美国国家卫生研究院;
关键词：
PANCREATIC DUCTAL ADENOCARCINOMA; PROLONGED PATIENT SURVIVAL; TRIPLE-NEGATIVE BREAST; MONOCLONAL-ANTIBODY K1; EXTRAHEPATIC BILE-DUCT; PHASE-I TRIAL; OVARIAN-CANCER; RECOMBINANT IMMUNOTOXIN; EXPRESSING MESOTHELIN; PLEURAL MESOTHELIOMA;
D O I：
10.1200/JCO.2016.68.3672
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Mesothelin is a tumor antigen that is highly expressed in many human cancers, including malignant mesothelioma and pancreatic, ovarian, and lung adenocarcinomas. It is an attractive target for cancer immunotherapy because its normal expression is limited to mesothelial cells, which are dispensable. Several antibody-based therapeutic agents as well as vaccine and T-cell therapies directed at mesothelin are undergoing clinical evaluation. These include antimesothelin immunotoxins (SS1P, RG7787/LMB-100), chimeric antimesothelin antibody (amatuximab), mesothelin-directed antibody drug conjugates (anetumab ravtansine, DMOT4039A, BMS-986148), live attenuated Listeria monocytogenes-expressing mesothelin (CRS-207, JNJ-64041757), and chimeric antigen receptor T-cell therapies. Two antimesothelin agents are currently in multicenter clinical registration trials for malignant mesothelioma: amatuximab in the first-line setting and anetumab ravtansine as second-line therapy. Phase II randomized clinical trials of CRS-207 as a boosting agent and in combination with immune checkpoint inhibition for pancreatic cancer are nearing completion. These ongoing studies will define the utility of mesothelin immunotherapy for treating cancer. (C) 2016 by American Society of Clinical Oncology
引用
收藏
页码：4171 / +
页数：10
相关论文
共 88 条
[1]   Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity [J].
Adusumilli, Prasad S. ;
Cherkassky, Leonid ;
Villena-Vargas, Jonathan ;
Colovos, Christos ;
Servais, Elliot ;
Plotkin, Jason ;
Jones, David R. ;
Sadelain, Michel .
SCIENCE TRANSLATIONAL MEDICINE, 2014, 6 (261)
[2]   Efficacy of RG7787, a Next-Generation Mesothelin-Targeted Immunotoxin, against Triple-Negative Breast and Gastric Cancers [J].
Alewine, Christine ;
Xiang, Laiman ;
Yamori, Takao ;
Niederfellner, Gerhard ;
Bosslet, Klaus ;
Pastan, Ira .
MOLECULAR CANCER THERAPEUTICS, 2014, 13 (11) :2653-2661
[3]   Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy [J].
Alvarez, Hector ;
Rojas, Pamela Leal ;
Yong, Ken-Tye ;
Ding, Hong ;
Xu, Gaixia ;
Prasad, Paras N. ;
Wang, Jean ;
Canto, Marcia ;
Eshleman, James R. ;
Montgomery, Elizabeth A. ;
Maitra, Anirban .
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2008, 4 (04) :295-301
[4]  
Argani P, 2001, CLIN CANCER RES, V7, P3862
[5]   Mesothelin expression correlates with prolonged patient survival in gastric cancer [J].
Baba, Kenji ;
Ishigami, Sumiya ;
Arigami, Takaaki ;
Uenosono, Yoshikazu ;
Okumura, Hiroshi ;
Matsumoto, Masataka ;
Kurahara, Hiroshi ;
Uchikado, Yuto ;
Kita, Yoshiaki ;
Kijima, Yuko ;
Kitazono, Masaki ;
Shinchi, Hiroyuki ;
Ueno, Shinichi ;
Natsugoe, Shoji .
JOURNAL OF SURGICAL ONCOLOGY, 2012, 105 (02) :195-199
[6]   Mesothelin-Specific Chimeric Antigen Receptor mRNA-Engineered T Cells Induce Antitumor Activity in Solid Malignancies [J].
Beatty, Gregory L. ;
Haas, Andrew R. ;
Maus, Marcela V. ;
Torigian, Drew A. ;
Soulen, Michael C. ;
Plesa, Gabriela ;
Chew, Anne ;
Zhao, Yangbing ;
Levine, Bruce L. ;
Albelda, Steven M. ;
Kalos, Michael ;
June, Carl H. .
CANCER IMMUNOLOGY RESEARCH, 2014, 2 (02) :112-120
[7]   Mesothelin is not required for normal mouse development or reproduction [J].
Bera, TK ;
Pastan, I .
MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (08) :2902-2906
[8]   Mesothelin confers pancreatic cancer cell resistance to TNF-α-induced apoptosis through Akt/PI3K/NF-κB activation and IL-6/Mcl-1 overexpression [J].
Bharadwaj, Uddalak ;
Marin-Muller, Christian ;
Li, Min ;
Chen, Changyi ;
Yao, Qizhi .
MOLECULAR CANCER, 2011, 10
[9]   Mesothelin overexpression promotes autocrine IL-6/sIL-6R trans-signaling to stimulate pancreatic cancer cell proliferation [J].
Bharadwaj, Uddalak ;
Marin-Muller, Christian ;
Li, Min ;
Chen, Changyi ;
Yao, Qizhi .
CARCINOGENESIS, 2011, 32 (07) :1013-1024
[10]   Listeria-based cancer vaccines that segregate immunogenicity from toxicity [J].
Brockstedt, DG ;
Giedlin, MA ;
Leong, ML ;
Bahjat, KS ;
Gao, Y ;
Luckett, W ;
Liu, WQ ;
Cook, DN ;
Portnoy, DA ;
Dubensky, TW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (38) :13832-13837
123456789